Company news

CNS Pharmaceuticals, Inc. news in 2021

CNS Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.

View company

CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

December 1, 2021

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)

September 29, 2021

CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook

August 12, 2021

CNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM

June 30, 2021

FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

June 28, 2021

CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index

June 16, 2021

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

May 18, 2021

CNS Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Outlook

May 13, 2021

CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021

February 24, 2021

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2021 Conference

January 6, 2021

Decks in 2021